

Pitolisant (oxalate)

Catalog No: tcsc1442



Available Sizes

Size: 10mg

Size: 50mg



Specifications

CAS No:

362665-57-4

Formula:

$C_{19}H_{28}ClNO_5$

Pathway:

Immunology/Inflammation;GPCR/G Protein

Target:

Histamine Receptor;Histamine Receptor

Purity / Grade:

>98%

Solubility:

DMSO : 50 mg/mL (129.57 mM; Need ultrasonic)

Alternative Names:

Tiprolisant oxalate

Observed Molecular Weight:

385.88

Product Description


Pitolisant oxalate is a potent and selective nonimidazole inverse agonist at the recombinant human **histamine H3 receptor** (K_i =0.16 nM).

IC50 & Target: Ki: 0.16 nM (H3 receptor)^[1]

EC50: 1.5 nM (H3 receptor)^[1]

In Vitro: On the stimulation of guanosine 5'-O-(3-[³⁵S]thio)triphosphate binding to this receptor, Pitolisant (BF2.649) behaves as a competitive antagonist with a K_i value of 0.16 nM and as an inverse agonist with an EC_{50} value of 1.5 nM and an intrinsic activity ~50% higher than that of ciproxifan. Pitolisant displaces [¹²⁵I]iodoproxyfan binding from mouse brain cortical membranes with an IC_{50} value of 26.4 ± 4.5 nM. Taking into account the K_d value of the radioligand (161 ± 9 pM), the deduced K_i value for Pitolisant is 14 ± 1 nM. Pitolisant displaces [¹²⁵I]iodoproxyfan binding from membranes of rat glioma C6 cells stably expressing the human H_3 receptor with an IC_{50} value of 4.2 ± 0.2 nM. Taking into account the K_d value of the radioligand (50 ± 4 pM), the deduced K_i value for Pitolisant is 2.7 ± 0.5 nM. Pitolisant progressively reverses this response with a Hill coefficient close to unity and an IC_{50} value of 330 ± 68 nM, leading to a K_i value of 17 ± 4 nM. Pitolisant elicits a dose-dependent decrease of the basal-specific [³⁵S]GTPγS binding to membranes with a maximal effect corresponding to $75 \pm 1\%$ of the basal-specific binding and an EC_{50} value of 1.5 ± 0.1 nM^[1].

In Vivo: The administration of Pitolisant at a single dose of 10 mg/kg 30 min before a single dose of Olanzapine (2 mg/kg b.w.) also significantly affects immobility time in the FST. Subsequent administration of the aforementioned drug sequence in mice statistically significantly increases the duration of immobility in comparison to the time determined in the control group in the FST. It decreased locomotor activity as well. In contrast, the results obtained in subchronic treatment after fifteen administrations of both drugs (Pitolisant 10 mg/kg b.w., and after 30 min Olanzapine 2 mg/kg b.w., and again after 4 h Olanzapine 2 mg/kg b.w.) show that the administration of Pitolisant followed by that of Olanzapine equalized the locomotor activity in mice; in comparison to the level of motility in the control group, to which only Pitolisant is administered. More importantly, this combination of drugs significantly reduces immobility time to the level obtained in the control group in the forced swim test in mice [one-way ANOVA; $F_{(3,20)} = 4.226, P = 0.0181$]^[2]. Rats given Pitolisant (10 mg/kg) during the conditioning phase stayed 502 ± 94 s on the paired texture, a value not statistically different from that of controls, indicating that Pitolisant did not support place preference^[3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!